Search

Your search keyword '"J. Mosquera"' showing total 15 results
Start Over Author "J. Mosquera" Journal annals of oncology
15 results on '"J. Mosquera"'

1. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Author

Casarrubios, M., primary, Cruz-Bermudez, A., additional, Sierra-Rodero, B., additional, Martinez, C., additional, Nadal, E., additional, Insa Molla, M.A., additional, Martinez, J. Mosquera, additional, Ojea, C. Gonzalez, additional, Gomez, M. Domine, additional, Tarruella, M. Majem, additional, Abreu, D. Rodriguez, additional, Martinez-Marti, A., additional, De Castro Carpeno, J., additional, Dols, M. Cobo, additional, Vivanco, G. Lopez, additional, Caro, R. Bernabe, additional, Segarra, N. Vinolas, additional, Aranda, I.C. Barneto, additional, Sureda, B. Massuti, additional, and Pulla, M. Provencio, additional

Published
2022
Full Text
View/download PDF

2. 939P Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial

Author

M. Casarrubios, A. Cruz-Bermudez, B. Sierra-Rodero, C. Martinez, E. Nadal, M.A. Insa Molla, J. Mosquera Martinez, C. Gonzalez Ojea, M. Domine Gomez, M. Majem Tarruella, D. Rodriguez Abreu, A. Martinez-Marti, J. De Castro Carpeno, M. Cobo Dols, G. Lopez Vivanco, R. Bernabe Caro, N. Vinolas Segarra, I.C. Barneto Aranda, B. Massuti Sureda, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

3. 1098P Predictive factors of efficacy to pembrolizumab in advanced NSCLC patients with high PD-L1 expression

Author

A. Piedra, A. Barba Joaquín, J. Mosquera Martinez, M. Fernandez Bruno, P. Cordeiro González, I.G. Sullivan, M. Riudavets Melia, M. Aguado Sorolla, P. Gallardo Melo, B. Martin Cullell, J. Gavira, J.C. Tapia, A. Romano, F. Bosma, S. Sanchez Del Rio, J. Sanz Beltran, M.A. Molina Pérez, J. Serra López, M.R. Garcia Campelo, and M. Majem Tarruella

Subjects
Oncology, Hematology
Published
2022

5. 1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

Author

Franco, F.F., primary, Carcereny, E., additional, Castro, R. Lopez, additional, Rodriguez, D., additional, Dols, M.A. Cobo, additional, Caro, R. Bernabe, additional, Cordellat, A. Blasco, additional, Sureda, B. Massuti, additional, Granados, A.L. Ortega, additional, Barco, E. del, additional, Bosch-Barrera, J., additional, Guirado, M., additional, Gonzalez-Larriba, J.L., additional, Vidal, O. Juan, additional, Martinez, J. Mosquera, additional, Rodriguez, J.M. Oramas, additional, Gonzalez, M.A. Sala, additional, Calvo, V., additional, Gonzalez, A. Estival, additional, and Provencio, M., additional

Published
2021
Full Text
View/download PDF

6. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

Author

Melia, M. Riudavets, primary, Auclin, E., additional, Lamas, M.A. Mosteiro, additional, Dempsey, N., additional, Majem, M., additional, Lobefaro, R., additional, Castro, R. Lopez, additional, Barrera, J. Bosch, additional, Pilotto, S., additional, Martín, E. Escalera, additional, Tagliamento, M., additional, Martinez, J. Mosquera, additional, Zalcman, G., additional, Nadal, E., additional, Lopes, G., additional, Signorelli, D., additional, Campelo, M.R. Garcia, additional, Besse, B., additional, Planchard, D., additional, and Mezquita, L., additional

Published
2021
Full Text
View/download PDF

8. 53P Second-line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)

Author

E. Carcereny Costa, A. Collazo Lorduy, M. Cobo Dols, D. Rodriguez Abreu, R. Bernabé Caro, R. Lopez Castro, B. Massuti Sureda, E. del Barco, M. Guirado, J. Bosch-Barrera, J.L. Gonzalez-Larriba, A. Sanchez Hernandez, O.J. Juan Vidal, J.M. Oramas Rodriguez, J. Mosquera Martinez, A.L.O. Ortega Granados, A. Padilla, M.T. Moran Bueno, A. Cantero, and M. Provencio Pulla

Subjects
Oncology, Hematology
Published
2022

9. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

Author

Ernest Nadal, Gilberto Lopes, Laura Mezquita, R. Lopez Castro, Benjamin Besse, J. Mosquera Martinez, E. Escalera Martín, R. Lobefaro, M.R. Garcia Campelo, N. Dempsey, M. Riudavets Melia, Diego Signorelli, M. Tagliamento, Sara Pilotto, M.A. Mosteiro Lamas, J. Bosch Barrera, David Planchard, G. Zalcman, Margarita Majem, and Edouard Auclin

Subjects
Oncology, medicine.medical_specialty, Durvalumab, Consolidation (soil), business.industry, Internal medicine, Medicine, In patient, Hematology, Stage (cooking), business
Published
2021

10. 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I

Author

S. Ponce Aix, E. Carcereny Costa, J. Bosch-Barrera, E. Felip Font, M. Guirado, J. Coves Sarto, M. Majem Tarruella, O.J. Juan Vidal, E. Dalmau Portulas, P. Diz, A.L.O. Ortega Granados, M. Domine Gomez, A. Blasco Cordellat, J. Mosquera Martinez, M.A. Sala Gonzalez, M. Dorta, V. Calvo de Juan, J. Zugazagoitia, A.B. Enguita, and L. Paz-Ares

Subjects
Oncology, Hematology
Published
2021

11. 1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

Author

R. Lopez Castro, R. Bernabe Caro, E. Del Barco, F. Franco, J. Mosquera Martinez, B. Massuti Sureda, M.A. Sala Gonzalez, Dora Rodríguez, Joaquim Bosch-Barrera, A. Blasco Cordellat, V. Calvo, O.J. Juan Vidal, J.M. Oramas Rodriguez, Jose-Luis Gonzalez-Larriba, M. Cobo Dols, Enric Carcereny, M. Guirado, A.L. Ortega Granados, M. Provencio, and A. Estival Gonzalez

Subjects
Oncology, Transthyretin, medicine.medical_specialty, biology, business.industry, Internal medicine, medicine, biology.protein, Hematology, Lung cancer, medicine.disease, business
Published
2021

12. Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer

Author

Martinez, J Mosquera, primary, Riuvadets, M., additional, García- Campelo, M.-R., additional, Lopez, J Serra, additional, Palacios, G Anguera, additional, Melo, P Gallardo, additional, Sullivan, I., additional, Joaquin, A Barba, additional, Tarruella, M Majem, additional, Rendo, C Reboredo, additional, and González, P Cordeiro, additional

Published
2019
Full Text
View/download PDF

13. 1786P Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study)

Author

J. Mosquera Martinez, R. Alonso, E. Nogueron Martinez, A. Sanchez Hernandez, R. Bernabe Caro, O. Juan-Vidal, C. Guirao Rubio, R. Lopez Castro, Virginia Calvo, Delvys Rodriguez-Abreu, M.A. Sala Gonzalez, J.M. Oramas Rodriguez, R. Blanco Guerrero, A.L. Ortega Granados, E. del Barco Morillo, M. Guirado, M. Provencio Pulla, P. Diz Tain, C. Garcia Benito, and E. Carcereny Costa

Subjects
Oncology, medicine.medical_specialty, Transthyretin, biology, business.industry, Internal medicine, medicine, biology.protein, Hematology, Extensive stage, Non small cell, business
Published
2020

14. Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer

Author

C. Reboredo Rendo, I. Sullivan, G. Anguera Palacios, M. Riuvadets, M. Majem Tarruella, J. Serra López, P. Gallardo Melo, M.R. Garcia Campelo, A. Barba Joaquín, J. Mosquera Martinez, and P Cordeiro González

Subjects
0301 basic medicine, medicine.medical_specialty, medicine.drug_class, Population, Antibiotics, 03 medical and health sciences, 0302 clinical medicine, Prednisone, Internal medicine, medicine, Lung cancer, education, Dexamethasone, education.field_of_study, business.industry, Medical record, Hematology, medicine.disease, Penicillin, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Corticosteroid, business, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

Background Immune-checkpoint inhibitors (ICIs) are a standard-of-care in advanced non-small cell lung cancer (NSCLC). Corticosteroids are often used in symptomatic patients, but their immunosuppressive effect may reduce the efficacy of ICIs. We report our experience in NSCLC and the potential impact of on-treatment use of corticosteroids and antibiotics. Methods Medical records of 267 patients with advanced NSCLC receiving ICIs from March 2013 to August 2018 were reviewed. Corticosteroid usage at the time of initiation or during ICIs treatment and administration of antibiotics from 3 months before the initiation of ICIs to 3 months after treatment end were collected. Kaplan Meier and log-rank tests were used to evaluate progression-free (PFS) and overall survival (OS). A multivariable analysis was performed to study the influence of clinical characteristics on treatment efficacy. Results 146 patients (55%) received corticosteroids: 43% for the treatment of irAEs and 57% for the management of baseline conditions. Prednisone (40%) and dexamethasone (35%) were the most commonly used. Median dose of prednisone equivalent was 50mg daily, 92% received ≥10mg prednisone equivalent daily. Median duration of corticosteroids was 59 days. OS was longer in the group that did not receive corticosteroids or received Conclusions The use of ≥ 10mg of prednisone equivalent daily was associated with poorer outcomes, especially when given for baseline condition. No correlation was found between antibiotics and survival. Corticosteroids usage may identify a population with higher volume and aggressive tumors. Prudent use of corticosteroids needs to be warranted. Legal entity responsible for the study The authors. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results